Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 1, 2011, Pages 137-139

  Qi, Wei ^a   Harries, A D ^b,c   Hinderaker, S G ^b,d  

^a TIANJIN CENTERS FOR DISEASE CONTROL AND PREVENTION   (China)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

China; Culture; Drug susceptibility testing; Multidrug resistant tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CHINA; CROSS-SECTIONAL STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; HUMAN; LABORATORY TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; CHI-SQUARE DISTRIBUTION; CHINA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 78650141207     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Donald P R, van Helden P D. The global burden of tuberculosis - combating drug resistance in difficult times. N Engl J Med 2009; 360: 2393-2395.
2. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009.
3. Department of Disease Control, Ministry of Health. Operational guideline of national tuberculosis control program. Beijing, China: Ministry of Health, 2002.
4. General Administration of Quality Supervision, Inspection and Quarantine, People's Republic of China. Laboratories - general requirement for biosafety. Regulation GB 19489-2004. Beijing, China: AQSIQ, 2004.
5. Rieder H L, Martin Chonde T, Myking H, et al. The public health service national tuberculosis laboratory and the national laboratory network: minimum requirements, role and operation in a low-income country. Paris, France: International Union Against Tuberculosis and Lung Disease, 1998.
6. Wright A, Zignol M, van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-1873.
7. von Elm E, Altman D G, Egger M, Pocock S J, Gotzsche P C, Vandenbroucke J P, for the STROBE initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
8. Korenromp E L, Scano F, Williams B G, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampicin-based treatment: an analytic review. Clin Infect Dis 2003; 37: 101-112.
9. Harries A D, Michongwe J, Nyirenda T E, et al. Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. Int J Tuberc Lung Dis 2004; 8: 204-210.